Prostate specific antigen (PSA) was first reported in prostate tissue in 1970 [1] and was measured in human sera in 1980. [2] PSA is a serine protease that is a member of the human kallikrein family, and it is secreted by the prostatic epithelial cells. [3] Although the level of serum PSA is a valuable marker for the detection of prostate cancer, it can also be elevated in benign conditions, such as aging, prostate enlargement, benign prostatic hyperplasia (BPH) and prostatitis. [4] In this study, the characteristics of BPH patients who underwent prostate biopsies in response to elevated serum PSA levels were evaluated with respect to the presence of concomitant chronic prostatitis.
Materials and methods
A total of 214 patients with elevated PSA levels of >4 ng/mL underwent 12-core prostate biopsies between August 2008 and January 2010. Patients' characteristics, such as age and levels of free and total PSA, were recorded. Transrectal 12-core systematic biopsies were performed under ultrasonographic guidance, as described by Hodge et al., [5] and prostate volume was measured. Additional cores were sampled when hypoechoic lesions were encountered during transrectal ultrasonography. No abnormal digital rectal examination findings or symptoms suggestive of prostatitis were detected among the patients included in the study, and a single dose of quinolone was administered before the biopsy procedure.
Data were analyzed with the Statistical Packages for the Social Sciences 11.5 for Windows (SPSS 11.5) software. Associations between the groups were tested by Student's t-test, and a p value of less than 0.05 was defined as the level of statistical significance.
Results
Of the patients in this study, the mean values of age, total PSA, free PSA, free/total PSA percentage and prostatic volume were 63.99±7.12 years, 15.82±22.34 ng/mL, 2.36±3.30 ng/ml, 16.04±7.33%, and 55.63±2.10 cc, respectively. We performed 12-core prostatic biopsies because of elevated PSA levels (≥4.0 ng/mL). Histopathological evaluations indicated prostate cancer in 62 patients (28.97%), while BPH was reported in 92 patients (42.99%), and BPH with chronic prostatitis was detected in 60 patients (28.03%). PSA values were significantly higher in BPH patients with chronic prostatitis compared with the other patients (p=0.002), while no other significant difference was detected among the patients' characteristics (Table 1) .
When BPH patients were classified according to their PSA levels, chronic prostatitis was observed in older subjects with PSA levels of 4-9.9 ng/mL (p=0.036) ( Table 2) . However, among patients with PSA levels ≥10 ng/mL, no statistically significant differences were observed in terms of age, free/ total PSA percentage or prostatic volume (p=0.104, p=0.137 and p=0.896, respectively) ( Table 3) .
Discussion
In patients without cancer, previous research indicates that age, prostate size, BPH and prostatitis may cause elevated levels of serum PSA. [6] Prostatic inflammation, however, does not seem to cause a clinically significant change in the ratio of free to total PSA. [7, 8] For patients with mildly increased PSA levels (4-10 ng/mL), the most likely cause is BPH, rather than prostate cancer. Other benign conditions that can elevate serum PSA levels are acute urinary 
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retention, acute prostatitis and prostatic ischemia, [9] although discriminating prostate cancer from benign prostatic conditions in patients who have undergone interventions in the prostate is difficult. One report on this subject suggested that 3% of patients who have undergone surgeries for BPH will develop prostate cancer during their follow-up period. [10] BPH is a common disease in older men, as 40% to 70% of men over the age of 60 are suspected to have BPH, and the incidence of BPH is increasing along with increasing life expectancy and westernized diets. [11, 12] Prostatitis was classified into four distinct categories by an expert consensus conference of the National Institutes of Health (NIH) in 1995. Category IV, known as asymptomatic chronic prostatitis, is defined by the presence of inflammatory cells either in expressed prostate secretions or during histopathological examination of prostatic biopsies from asymptomatic men. [13, 14] Prostatic histopathology in the context of the chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has been analyzed in a prospective study by True et al. [15] In their study, 368 patients underwent prostatic biopsies. Chronic prostatitis was detected in 97 patients; however, no inflammatory cells were noted in 67% of the specimens. In fact, only 5% of patients' biopsies exhibited moderate or severe inflammation. In our study, histopathological analyses of patients who underwent prostatic biopsy because of elevated PSA levels demonstrated BPH in 42.9% of patients and BPH with chronic prostatitis (the asymptomatic patient group) in 28% of patients.
Carver et al. [16] determined the prevalence of category IV prostatitis on the basis of indications of inflammation present in expressed prostatic secretions in 300 randomly selected men participating in a prostate cancer awareness screening program. Of the 300 patients, 227 provided specimens for examination. The prevalence of inflammation was 32.2%, suggesting that category IV prostatitis is common. In addition, the investigators determined that men with category IV prostatitis exhibited a significantly higher level of serum PSA than did men with no evidence of prostatitis. Similarly, the incidence of chronic (category IV) prostatitis was 28.03% in our study group, which consisted of patients who reported no symptoms of prostatitis, had not been previously treated because of prostatitis and were subjected to prostatic biopsies only because of high PSA levels.
In another study, Okada et al. [17] evaluated 558 negative needle biopsy specimens obtained from 93 men without a diagnosis of prostate cancer or clinical prostatitis. Inflammation in the specimens was graded and correlated with levels of serum PSA. Serum PSA levels were observed to be significantly correlated with inflammation, particularly with acute inflammation. Similarly, Stancik et al. [18] studied needle biopsies from 404 patients and analyzed the correlation between their results and levels of total and free PSA in the serum. Although the authors could not detect significant differences in total PSA levels between patients with prostate cancer or with prostatitis, free/ total PSA ratios were significantly reduced in prostate cancer patients. In our study, patients without cancer (n=152, 71.02% of all patients) were determined histopathologically to exhibit BPH in 92 cases (42.99% of all patients) and BPH with chronic prostatitis (category IV prostatitis) in 60 cases (28.03% of all patients). Of these benign group patients, 102 exhibited PSA levels of between 4.0 and 9.9 ng/mL (47.66% of all patients), while 50 exhibited PSA levels ≥10.0 ng/mL (23.36% of all patients). Total PSA levels were significantly higher in BPH patients with chronic prostatitis, while no other significant difference was detected among the variables of our study (p=0.002).
In a similar study, Rowe et al. [19] examined the relationship between serum PSA levels and incidental prostatic inflammation. The authors evaluated prostate biopsy results from 175 men and observed that men with acute inflammation exhibited significantly higher ratios of free/total levels of serum PSA than did those with chronic inflammation or BPH. Furthermore, their study reported that the serum free/total PSA ratios were similar in patients with acute inflammation and prostate cancer. Another report indicated that biopsies taken from patients with levels of serum PSA higher than 4.0 ng/mL exhibited 72.5% category IV prostatitis. [20] In a similar study, Potts [21] suggested a screening for category IV prostatitis in men with elevated PSA because of the high prevalence of the disorder (42% in her series of 122 men). In addition, Potts [21] suggested treating the men with prostatitis with appropriate antibiotics and subsequently measuring serum PSA a second time. Four weeks of antibiotic therapy resulted in a 42% reduction in men requiring biopsies. From these results, Potts [21] recommended that antibiotics should only be used if bacterial prostatitis is suspected and that antibiotics should not be used to modulate the levels of serum PSA. This approach is suggested in patients with chronic nonbacterial prostatitis and in asymptomatic men. Particularly in asymptomatic screened men, the use of antibiotics to lower serum PSA is controversial and is probably not advisable. [22] The probability that antibiotics may lower the level of serum PSA in this case is ultimately no higher than the probability that the measurement of serum PSA may have been reduced because of natural fluctuations in serum PSA values. [22] All of the patients in our study exhibited chronic asymptomatic prostatitis. None of the patients were given premedication, except a single prophylactic dose of quinolone, because of the controversy surrounding treatment with antibiotics for high PSA levels in men with asymptomatic prostatitis.
On the other hand, histological prostatitis is a common finding among men without clinical prostatitis. Although acute inflammation has been reported to be necessary to induce elevated levels of PSA, a growing body of evidence indicates that subclinical inflammation may also be related to increased PSA levels. [23] Furthermore, several investigators have demonstrated that the treatment of chronic prostatitis, once identified, can decrease PSA levels, suggesting that the utilization of anti-microbial and/or anti-inflammatory drugs may reduce the necessity of prostate biopsies. [24] However, another report noted that 26.9% to 31% of patients presented with a decrease in PSA after the administration of antibiotics or a placebo harbor cancer, as demonstrated through prostate biopsies. Decreases in PSA levels do not indicate the absence of prostate cancer. [25] Currently, no standardized policy outlines the management of patients with elevated PSA levels. However, the treatment of such patients has provided some guidelines. The first guideline is the immediate referral for prostate biopsy, which discounts any potential role of inflammation in the etiology of increased PSA levels, as well as random PSA fluctuations. The second guideline is the immediate repetition of the PSA test. Importantly, chronic prostatitis may interfere with clinicians' interpretations of PSA levels when screening for prostate cancer. No general guidelines can be uniformly applied to all men with increased PSA levels before recommending prostate biopsy. However, an assessment of the patient's individual condition may result in an algorithmic change to improve the specificity of PSA concentration as a diagnostic tool for prostate cancer and may provide a more acceptable initial treatment than proceeding directly to prostate biopsies. With the support of multicenter, large-scale studies, our preliminary study may provide an algorithmic approach to treating symptomatic prostatitis.
This study indicates that elevated PSA levels may be associated with benign conditions, such as BPH and/or chronic asymptomatic prostatitis. When the PSA level is between 4.0 and 9.9 ng/mL, BPH patients with chronic prostatitis tend to be older, while prostatic volume and free/total PSA percentages were not significantly different in BPH patients with or without chronic prostatitis.
